Table 3.
Cox regression model* for the effect of continuous variables, including features of the metabolic syndrome as defined by ATPIII, on the risk of total CVD events in patients assigned to placebo in the FIELD study
| Variable† | Hazard ratio (95% CI) | P |
|---|---|---|
| Predictive variable | ||
| Female (at 62 years) | 0.70 (0.55-0.88) | 0.003 |
| Age (per 10 years): male | 1.21 (1.06-1.39) | < 0.001 |
| Age (per 10 years): female | 1.74 (1.38-2.19) | |
| Prior CVD (at 140 mmHg SBP, 6.85% HbA1c) | 2.14 (1.81-2.53) | < 0.001 |
| Hemoglobin A1c (per 1%): no prior CVD | 1.18 (1.10-1.26) | < 0.001 |
| Hemoglobin A1c (per 1%): prior CVD | 1.03 (0.95-1.13) | |
| Creatinine (per 20 μmol/L) | 1.21 (1.09-1.35) | < 0.001 |
| Metabolic syndrome variable‡ | ||
| Waist -hip ratio (per 0.1) | 1.03 (0.91-1.17) | 0.60 |
| Systolic BP (per 10 mmHg): no prior CVD | 1.16 (1.09-1.24) | < 0.001 |
| Systolic BP (per 10 mmHg): prior CVD | 1.01 (0.94-1.09) | |
| Triglycerides (per 0.5 mmol/L) | 1.03 (0.99-1.07) | 0.19 |
| HDL-c (per 0.1 mmol/L) | 0.94 (0.90-0.97) | < 0.001 |
| Urine albumin-creatinine ratio (per doubling) | 1.06 (1.02 - 1.10) | 0.002 |
* Cox proportional-hazards assumptions were met.
† All variables were centered at medians. Standard deviations for distributions of the continuous variables were: age, 6.9 years; HbA1c, 1.35%; creatinine, 15.8 μmol/L; waist, 13 cm; systolic BP, 15 mmHg; triglycerides, 0.88 mmol/L; HDL-c, 0.26 mmol/L.
‡ Corrected for age, sex, prior CVD, baseline HbA1c and creatinine.
ATPIII, Adult Treatment Panel III; CVD, cardiovascular disease; FIELD, Fenofibrate Intervention and Event Lowering in Diabetes; BP, blood pressure; HDL-c, high-density lipoprotein cholesterol